Equities Analysts Offer Predictions for TARS FY2024 Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Investment analysts at William Blair increased their FY2024 EPS estimates for shares of Tarsus Pharmaceuticals in a research note issued on Thursday, November 14th. William Blair analyst L. Hanbury-Brown now anticipates that the company will post earnings per share of ($3.26) for the year, up from their previous forecast of ($3.72). William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.41) per share. William Blair also issued estimates for Tarsus Pharmaceuticals’ Q4 2024 earnings at ($0.77) EPS, Q1 2025 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at $0.22 EPS and FY2025 earnings at ($0.96) EPS.

TARS has been the topic of several other reports. The Goldman Sachs Group lifted their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday. Oppenheimer lifted their price target on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $54.20.

Tarsus Pharmaceuticals Trading Down 3.9 %

Tarsus Pharmaceuticals stock opened at $44.83 on Monday. The company has a market cap of $1.71 billion, a P/E ratio of -11.77 and a beta of 1.00. Tarsus Pharmaceuticals has a 1 year low of $15.60 and a 1 year high of $52.99. The firm’s 50-day moving average is $37.84 and its 200-day moving average is $32.53. The company has a debt-to-equity ratio of 0.30, a quick ratio of 6.99 and a current ratio of 5.42.

Institutional Trading of Tarsus Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Swiss National Bank increased its position in Tarsus Pharmaceuticals by 1.4% in the 1st quarter. Swiss National Bank now owns 42,433 shares of the company’s stock worth $1,542,000 after buying an additional 600 shares during the period. Alpha DNA Investment Management LLC raised its stake in shares of Tarsus Pharmaceuticals by 9.1% in the 2nd quarter. Alpha DNA Investment Management LLC now owns 15,174 shares of the company’s stock valued at $412,000 after buying an additional 1,261 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Tarsus Pharmaceuticals by 33.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock worth $166,000 after purchasing an additional 1,530 shares in the last quarter. Profund Advisors LLC lifted its position in shares of Tarsus Pharmaceuticals by 26.8% during the 2nd quarter. Profund Advisors LLC now owns 9,126 shares of the company’s stock worth $248,000 after buying an additional 1,929 shares during the period. Finally, Quest Partners LLC bought a new position in shares of Tarsus Pharmaceuticals during the second quarter valued at $61,000. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.